Last updated: August 2, 2026
QLOSI is a prescription, preservative-free pilocarpine hydrochloride ophthalmic solution 0.4% approved by the FDA for the treatment of presbyopia in adults. Its commercial opportunity is substantial because presbyopia affects most adults over 40, but market performance depends on patient willingness to use daily topical therapy, reimbursement, optometrist adoption, and competition from Vuity and newer presbyopia products. QLOSI’s financial trajectory cannot be quantified from audited public revenue disclosures because Orasis Pharmaceuticals is privately held and has not reported product-level sales in public-company filings.
What is QLOSI and how does it work?
QLOSI is a low-concentration pilocarpine eye drop developed by Orasis Pharmaceuticals. The product received FDA approval on October 17, 2023, under New Drug Application 214028 for the treatment of presbyopia in adults.[1]
QLOSI uses pilocarpine, a muscarinic agonist. By constricting the pupil, the product increases depth of focus and improves near vision without correcting the underlying loss of lens accommodation associated with presbyopia.
The approved regimen is one drop in each affected eye twice daily, approximately six hours apart. The product is preservative-free and supplied in single-use containers. Its label identifies blurred vision, headache, instillation-site irritation, and visual disturbances as relevant adverse reactions.[2]
| Product attribute |
QLOSI profile |
| Active ingredient |
Pilocarpine hydrochloride |
| Strength |
0.4% |
| Dosage form |
Ophthalmic solution |
| FDA indication |
Presbyopia in adults |
| Administration |
One drop per affected eye twice daily |
| Preservatives |
Preservative-free, single-use packaging |
| Sponsor |
Orasis Pharmaceuticals |
| FDA approval |
October 17, 2023 |
| Regulatory pathway |
505(b)(2) NDA |
| Primary commercial market |
U.S. prescription ophthalmology and optometry |
What is the U.S. market opportunity for QLOSI?
The addressable population is large, but the treated market will be materially smaller than the total presbyopic population.
The United States has tens of millions of adults with presbyopia. Most manage the condition with reading glasses, multifocal contact lenses, progressive spectacles, or surgical procedures. QLOSI therefore competes against established consumer and medical alternatives rather than addressing an untreated market.
The commercial opportunity has four layers:
- Adults seeking temporary improvement in near vision without glasses.
- Patients dissatisfied with progressive lenses or contact lenses.
- Consumers who are willing to pay cash for convenience.
- Ophthalmology and optometry practices seeking a pharmacologic option before surgical treatment.
QLOSI’s market penetration will depend on whether patients view twice-daily dosing as a meaningful improvement over glasses. The product has a stronger commercial position among patients who value intermittent near-vision enhancement, particularly for work, dining, driving-related activities, or social settings.
Pricing and reimbursement will be decisive. Presbyopia treatment is often classified as an elective or nonessential benefit, making commercial insurance coverage uncertain. A high cash price would limit adoption and increase dependence on manufacturer coupons, patient-assistance programs, and employer or flexible-spending accounts.
How does QLOSI compare with Vuity and other presbyopia drugs?
QLOSI entered a market established by Vuity, AbbVie’s pilocarpine hydrochloride ophthalmic solution 1.25%. Vuity was the first FDA-approved prescription eye drop specifically indicated for age-related blurry near vision associated with presbyopia.[3]
| Factor |
QLOSI |
Vuity |
| Sponsor |
Orasis Pharmaceuticals |
AbbVie |
| Active ingredient |
Pilocarpine hydrochloride |
Pilocarpine hydrochloride |
| Strength |
0.4% |
1.25% |
| FDA approval |
2023 |
2021 |
| Dosing |
Twice daily |
Once daily |
| Preservative profile |
Preservative-free single-use product |
Multidose ophthalmic formulation |
| Commercial position |
New entrant |
First-mover brand |
| Primary differentiation |
Lower concentration and preservative-free delivery |
Once-daily dosing and established market presence |
QLOSI’s lower concentration may support tolerability for some patients, while its preservative-free packaging may appeal to patients with ocular-surface sensitivity. Twice-daily dosing is a commercial disadvantage relative to Vuity’s once-daily regimen.
The competitive comparison is not limited to concentration. Patients and prescribers will evaluate:
- Near-vision improvement.
- Duration of effect.
- Night-vision effects.
- Headache and ocular discomfort.
- Frequency of administration.
- Cost per month.
- Availability through pharmacies.
- Sample access and patient support.
- Prescriber confidence in long-term use.
The future competitive landscape also includes investigational or recently approved agents using different pharmacologic approaches, including aceclidine-based products. These products could compete directly with pilocarpine if they deliver a broader visual field, longer duration, or improved tolerability.
What FDA regulatory status does QLOSI have?
QLOSI has full FDA approval for its labeled indication. It is not an over-the-counter product, a biologic, or a biosimilar. The FDA approved the product through a 505(b)(2) application, a pathway that permits reliance in part on existing scientific information while requiring product-specific evidence.[1]
The regulatory profile has several commercial implications:
- The indication is limited to presbyopia in adults.
- Promotional claims must remain within the approved label.
- Any new strength, dosing schedule, or indication would require additional FDA review.
- A sponsor seeking pediatric, broader ophthalmic, or combination claims would need supporting regulatory submissions.
- Postmarketing pharmacovigilance remains relevant because pilocarpine can produce visual disturbances and systemic cholinergic effects.
QLOSI is not interchangeable with Vuity solely because both contain pilocarpine. Interchangeability and substitution depend on product-specific regulatory designations, dosage form, concentration, labeling, and state pharmacy rules.
What patents protect QLOSI?
QLOSI’s protection is likely to depend on a combination of formulation, dosing, delivery, and method-of-use rights rather than only the active ingredient. Pilocarpine is an established compound and cannot provide meaningful new-molecule exclusivity for QLOSI.
Potential protection categories include:
- Low-concentration pilocarpine formulations for presbyopia.
- Preservative-free single-use ophthalmic packaging.
- Dosing schedules using twice-daily administration.
- Methods for improving near vision while limiting adverse visual effects.
- Formulation stability and manufacturing processes.
- Specific combinations of concentration, dosing interval, and patient population.
The relevant U.S. regulatory exclusivity period is five years for a new chemical entity only if the product qualifies for that designation. QLOSI’s use of an established active ingredient and 505(b)(2) pathway means its effective exclusivity framework is more likely to depend on patents and any applicable three-year clinical-investigation exclusivity than on five-year NCE exclusivity.[4]
A definitive Orange Book patent analysis requires review of the FDA’s current Orange Book listing for NDA 214028 and the underlying U.S. Patent and Trademark Office records. Public commercial materials do not establish a reliable, complete list of QLOSI patent numbers, expiration dates, terminal disclaimers, or pediatric extensions. No unsupported patent number or expiration date should be used in a freedom-to-operate or Paragraph IV assessment.
When could generic QLOSI entry occur?
Generic entry risk is governed by three separate factors:
- FDA approval and regulatory exclusivity.
- Listed patent claims and their expiration dates.
- The commercial and technical difficulty of reproducing the product.
A generic sponsor could use an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence. If the formulation, packaging, or clinical-use claims create regulatory complexity, a 505(b)(2) application could be considered instead.
The main barriers are likely to include:
- Demonstrating equivalence for a low-dose ophthalmic solution.
- Matching preservative-free single-use delivery.
- Establishing container-closure compatibility.
- Reproducing pH, osmolality, viscosity, and stability.
- Addressing method-of-use claims for presbyopia.
- Avoiding valid formulation or manufacturing patents.
A Paragraph IV challenge could arise before patent expiry if a generic sponsor believes the listed patents are invalid, unenforceable, or not infringed. The commercial value of such a challenge depends on the size of QLOSI sales by the time of filing. A small branded market can reduce the incentive to incur litigation costs.
What patent litigation and settlement agreements affect QLOSI?
No major publicly reported QLOSI Paragraph IV litigation or settlement agreement is established in the cited FDA and company materials. There is also no identified public biosimilar pathway because QLOSI is a small-molecule ophthalmic product, not a biologic.
The principal litigation risk is therefore expected to be ordinary Hatch-Waxman patent litigation if an ANDA sponsor files a Paragraph IV certification. Other possible disputes include:
- Patent ownership or inventorship challenges.
- Trade-secret claims involving formulation or manufacturing.
- Trademark disputes.
- Commercial disputes involving licensing, distribution, or promotion.
- Product-liability litigation concerning visual disturbances or ocular adverse events.
The absence of a reported settlement does not establish that no private agreement exists. Private commercial contracts are not necessarily disclosed.
Which companies are challenging QLOSI commercially?
The most direct branded competitor is AbbVie’s Vuity. The broader competitive set includes:
- Reading-glass and progressive-lens manufacturers.
- Multifocal and monovision contact-lens providers.
- Refractive-surgery providers.
- Corneal inlay and lens-based surgical technologies.
- Developers of pharmacologic presbyopia treatments.
- Potential generic pilocarpine ophthalmic manufacturers.
QLOSI has a smaller commercial infrastructure than AbbVie. That creates a disadvantage in sales-force coverage, payer contracting, consumer advertising, and pharmacy distribution. Orasis can offset part of that disadvantage through ophthalmology-focused promotion, specialty pharmacy partnerships, digital prescribing, and targeted sampling.
What is the financial trajectory for QLOSI?
QLOSI’s public financial trajectory is best characterized as pre-scale commercialization rather than mature branded-pharmaceutical performance.
| Financial factor |
Likely effect on QLOSI |
| Product launch stage |
High selling and marketing costs relative to revenue |
| Sponsor ownership |
Limited public disclosure because Orasis is private |
| Revenue visibility |
No audited product-level revenue publicly available |
| Gross margin |
Potentially attractive for a topical ophthalmic product after scale |
| Near-term cash burn |
Likely elevated because of launch investment |
| Reimbursement |
Could materially affect prescription conversion |
| Patient acquisition cost |
Likely high in a new elective category |
| Competitive pressure |
Strong from Vuity and future entrants |
| Manufacturing |
Single-use ophthalmic packaging can raise unit costs |
| Strategic value |
Depends on prescription growth, repeat use, and payer acceptance |
The initial financial profile is likely to show substantial investment in commercial infrastructure before the product reaches operating leverage. Costs include sales representatives, medical-affairs personnel, market access, sampling, patient-support programs, manufacturing scale-up, distribution, and postmarketing activities.
Revenue quality will matter more than prescription volume alone. Key metrics include:
- New prescriptions.
- Refill rate.
- Persistency after the first month.
- Average net price.
- Gross-to-net deductions.
- Cash-pay conversion.
- Commercial insurance coverage.
- Prescriber concentration.
- Repeat use per patient.
- Cost of customer acquisition.
QLOSI could reach attractive economics if it achieves high refill persistence and a favorable net price. The product’s twice-daily schedule and elective indication create a risk that patients will try it once but discontinue after experiencing limited benefit, adverse effects, or high out-of-pocket costs.
How strong is the QLOSI commercial and patent estate?
QLOSI’s commercial estate is differentiated but exposed.
Its strengths are:
- FDA approval for a large prevalent condition.
- Preservative-free single-use presentation.
- Lower pilocarpine concentration than Vuity.
- A product-specific clinical and regulatory package.
- Potential appeal among patients seeking an alternative to glasses.
Its weaknesses are:
- Established nonpharmaceutical substitutes.
- Twice-daily dosing.
- Lack of new-molecule exclusivity.
- Limited public evidence of large-scale commercial traction.
- Dependence on patient self-pay or uncertain reimbursement.
- Smaller sponsor resources than AbbVie.
- Potential generic competition after relevant protection expires.
The patent estate should be assessed claim by claim. Method-of-use claims may provide meaningful protection against labeled use but can be difficult to enforce against generic products because of skinny-label strategies. Formulation claims may offer stronger practical protection if the generic must reproduce the same low-concentration, preservative-free product to compete effectively.
What generic launch scenarios exist for QLOSI?
Three scenarios are commercially relevant.
Early Paragraph IV challenge
A generic sponsor files an ANDA before the branded patents expire and challenges the listed claims. Litigation could delay approval or create a settlement-based entry date. The incentive would increase if QLOSI prescriptions grow rapidly.
At-risk launch
A generic launches before all patent disputes are resolved. This could expose the sponsor to damages and an injunction, making the scenario less likely unless the patent estate appears weak.
Post-expiry entry
Generic entry follows patent expiry or a settlement date. Price erosion would depend on the number of entrants, the ease of manufacturing the single-use presentation, and the degree of pharmacy substitution.
For QLOSI, the most important generic barrier may be the combination of formulation complexity and limited market size. Technical difficulty can delay entry, while limited revenue can reduce the economic incentive to challenge.
What licensing or strategic transactions affect QLOSI?
QLOSI was developed by Orasis Pharmaceuticals. Orasis has funded development through private financing and strategic investment, but public materials cited here do not establish a disclosed transaction transferring QLOSI rights to a major pharmaceutical company.
A licensing or acquisition transaction would likely be driven by:
- Prescription growth.
- Net revenue retention.
- Payer coverage.
- Evidence of repeat use.
- Manufacturing reliability.
- The strength and term of formulation patents.
- International rights outside the United States.
Geographic expansion would require country-specific regulatory approvals, pricing strategies, and patent analysis. U.S. approval does not authorize marketing in Europe, Canada, Japan, or other jurisdictions. The commercial case outside the U.S. may depend on whether regulators accept the same clinical package and whether presbyopia drops receive reimbursement.
Key Takeaways
- QLOSI is an FDA-approved, preservative-free pilocarpine 0.4% ophthalmic solution for adult presbyopia.
- Its main branded competitor is AbbVie’s once-daily Vuity.
- QLOSI’s commercial differentiation is its lower concentration and single-use preservative-free format, while twice-daily dosing is a disadvantage.
- The U.S. opportunity is large, but glasses, contact lenses, surgery, and cash-pay economics constrain conversion.
- Orasis is privately held, and reliable public product-level revenue data are not available.
- QLOSI does not rely on new-molecule exclusivity; formulation, delivery, dosing, and method-of-use patents are more important.
- No major publicly reported QLOSI Paragraph IV litigation or settlement is identified in the cited sources.
- Financial performance will depend on refill persistence, reimbursement, net price, manufacturing cost, and prescriber adoption.
- Generic risk is likely to emerge through an ANDA and Paragraph IV strategy once listed patent and regulatory protections become commercially meaningful.
FAQs About QLOSI Market and Patent Risk
Is QLOSI covered by insurance?
Coverage varies by plan and may be limited because presbyopia treatment is frequently treated as an elective benefit. Patient out-of-pocket cost is likely to influence initial use and refill persistence.
Is QLOSI better than Vuity?
Neither product is universally superior. QLOSI offers a lower concentration and preservative-free single-use packaging, while Vuity offers once-daily dosing and longer commercial experience.
Is QLOSI a biologic or biosimilar?
No. QLOSI is a small-molecule ophthalmic drug. Biosimilar rules do not apply.
Can a generic company copy QLOSI’s preservative-free packaging?
A generic sponsor would need to satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, container closure, stability, and manufacturing quality. Valid formulation or packaging patents could create further barriers.
What will determine QLOSI’s long-term value?
The most important variables are sustained prescription growth, repeat use, net pricing, payer coverage, adverse-event rates, competition from newer presbyopia drugs, and the remaining life of formulation and method-of-use patents.
References
-
U.S. Food and Drug Administration. (2023). QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%: Approval announcement and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). QLOSI prescribing information. FDA.
-
U.S. Food and Drug Administration. (2021). FDA approves first prescription medication for age-related blurry near vision. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Orasis Pharmaceuticals. (2023). Orasis Pharmaceuticals announces FDA approval of QLOSI for the treatment of presbyopia. Company press release.
